A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)
This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.
• Willing and able to provide written informed consent form
• Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form
• Generally healthy on medical history, exam, labs, and ECG
• BCVA 20/25 or better in each eye
• Serum retinol above protocol threshold
• Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2
• Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period
• Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status
• Participants aged 12 to 45 years
• Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant
• Minimum BCVA is required in the study eye
• Subjects must have a defined aggregate atrophic lesion in 1 or both eyes
• Body weight ≥40 kg
• Able to complete key ophthalmic safety assessments and comply with study precautions